Artimplant AB clears royalty rights for Artelon®

Västra Frölunda, Sweden, September 26, 2007
The biomaterials company Artimplant clears royalty rights for the biomaterial Artelon®. With effect from January 1, 2007 this improves Artimplant’s margin on license income from product sales by five percentage points.

Artimplant AB clears royalty rights for the basic patent for the biomaterial platform Artelon®. The present holder, Polyrand AB, receives SEK 2,750,000 to clear the agreement containing the rights. With effect from January 1, 2007 this improves Artimplant's margin on license income from product sales by five percentage points. Artimplant currently receives license income from Small Bone Innovations, Inc. in respect of sales of Artelon® Spacer and from Biomet Sports Medicine in respect of sales of SportMesh™ Soft Tissue Reinforcement. The payment to Polyrand will be charged to Artimplant's cash reserves and will be recorded as a patent investment during the fourth quarter of 2007.

Polyrand AB was founded by the late Per Flodin, the person behind the basic patent for Artelon®. Per Flodin was professor emeritus in polymer technology at Chalmers University of Technology.